Novoseven


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to Novoseven: FEIBA, Novoeight

NovoSeven®

Hematology A recombinant coagulation factor VIIa indicated for treating bleeding episodes in hemophilia A or B Pts with antibodies to coagulation factors VIII or IX

Novoseven

A brand name for EPTACOG ALFA (Factor VIIa).
References in periodicals archive ?
Professor Ian Roberts, of the London School of Hygiene and Tropical Medicine, has written to Des Browne asking why NovoSeven has been approved for use on troops.
Brewin et al., 2000 Elseguimiento de 1 ano de 6 ninos con h con inhibidor, indico que el tratamiento con rFVIIa (NovoSeven) ademanda, equiparala CdV de los ninos con inhibidor ala de los ninos sin esta complicacion.
The patients in the study, which was funded by Novo Nordisk, the maker of NovoSeven, had ICH confirmed by CT within 3 hours of onset; treatment was administered within 1 hour of the baseline scan.
The facility will cover formulation, freeze-drying, filling and packaging of a range of Novo Nordisk's biopharmaceuticals, including the haemophilia medicine NovoSeven, the growth hormone Norditropin and the glucagon product GlucaGen.
We determined the clinical response and the cost of treatment with NovoSeven in three patients with low titer inhibitors to factors VIII compared with other treatment regime previously used in these patients (Plasma derived factor VIII).
9 December 2010 - Danish Novo Nordisk (CPH: NOVO B) said on Tuesday it has presented data from a Phase II study evaluating the safety, pharmacokinetics and efficacy of a recombinant factor VIIa (rFVIIa) analogue, designed to have a faster action profile than NovoSeven (rFVIIa) in hemophilia patients with inhibitors (antibody formation against factor preparations).
En el escenario actual tenemos el rol de un medicamento que, para muchos, ha referido un resultado milagroso en el control de la coagulopatia, siendo este: el factor VII recombinante activado o NovoSeven, Novo Nordisk, Bagsvaerd, Denmark (rFVIIa).
This promising systemic agent (NovoSeven; Novo Nordisk US, Princeton, NJ) binds to tissue factors that are exposed at sites of vessel injury.
Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven).
NovoSeven Coagulation Factor VIIa (Recombinant) was approved in 1999 to treat bleeding episodes in hemophilia A or B patients with clotting inhibitors to Factor VIII or Factor IX.
She has extensive experience in the hematology arena and will oversee efforts with NovoSeven, a general hemostatic agent.
Contract notice: supply of medicinal products for uhkt - novoseven